This result suggests that all of the amplified copies of EGFR in the mutant samples contain the mutation (i.e., that only the mutant allele undergoes amplification) and that mutations occur as an early triggering event, making EGFR amplification beneficial for cancer. The gene discussed is EGFR; the disease is cancer.